title: Transient hypothyroidism after iodine-131 therapy for Grave's disease.
abstract: We studied 355 patients with Grave's disease to characterize transient hypothyroidism and its prognostic value following 131I therapy.
  
  
  METHODS
  The patients received therapeutic 131I treatment as follows: 333 received a dose < 10 mCi (6.6 +/- 1.9 mCi) and 22 received a dose > 10 mCi (12.8 +/- 2.9 mCi). Diagnosis of transient hypothyroidism was based on low T4, regardless of TSH within the first year after 131I followed by recovery of T4 and normal TSH.
  
  
  RESULTS
  After administration of < 10 mCi 131I, 40 patients developed transient hypothyroidism during the first year; transient hypothyroidism was symptomatic in 15. There was no transient hypothyroidism after high doses (> 10 mCi) of 131I. Iodine-131 uptake > 70% at 2 hr before treatment was a risk factor for developing transient hypothyroidism (Odds ratio 2.8, 95% confidence interval 0.9-9.4). At diagnosis of transient hypothyroidism, basal TSH levels were high (51%), normal (35%) or low (14%); therefore, the transient hypothyroidism was not centralized. If hypothyroidism developed during the first 6 mo after basal TSH > 45 mU/liter ruled out transient hypothyroidism.
  
  
  CONCLUSIONS
  The development of transient hypothyroidism and its hormonal pattern did not influence long-term thyroid function. Since no prognostic factors reliably predicted transient hypothyroidism before 131I or at the time of diagnosis, if hypothyroidism appears within the first months after 131I, the reevaluation of thyroid function later is warranted to avoid unnecessary chronic replacement therapy.
authors.affiliation: Department of Endocrinology, Ciutat Sanitària, Barcelona, Spain.
authors.forename: N
authors.initials: N
authors.lastname: Gómez
authors.forename: J M
authors.initials: JM
authors.lastname: Gómez
authors.forename: A
authors.initials: A
authors.lastname: Orti
authors.forename: L
authors.initials: L
authors.lastname: Gavaldà
authors.forename: C
authors.initials: C
authors.lastname: Villabona
authors.forename: P
authors.initials: P
authors.lastname: Leyes
authors.forename: J
authors.initials: J
authors.lastname: Soler
mesh_terms: D005260:Female; D006111:Graves Disease / Q000532:radiotherapy*; D006801:Humans; D007037:Hypothyroidism / Q000097:blood / Q000209:etiology*; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D012307:Risk Factors; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
chemical_list: D007457:Iodine Radioisotopes; D014284:Triiodothyronine; D013972:Thyrotropin; D013974:Thyroxine